235 related articles for article (PubMed ID: 19072396)
1. Pharmacology, clinical efficacy and safety of lamivudine in hepatitis B virus infection.
Kumar M; Sarin SK
Expert Rev Gastroenterol Hepatol; 2008 Aug; 2(4):465-95. PubMed ID: 19072396
[TBL] [Abstract][Full Text] [Related]
2. A 7-year study of lamivudine therapy for hepatitis B virus e antigen-positive chronic hepatitis B patients in China.
Yao GB; Zhu M; Cui ZY; Wang BE; Yao JL; Zeng MD
J Dig Dis; 2009 May; 10(2):131-7. PubMed ID: 19426396
[TBL] [Abstract][Full Text] [Related]
3. Current therapy with nucleoside/nucleotide analogs for patients with chronic hepatitis B.
Xu XW; Chen YG
Hepatobiliary Pancreat Dis Int; 2006 Aug; 5(3):350-9. PubMed ID: 16911930
[TBL] [Abstract][Full Text] [Related]
4. Long-term lamivudine treatment of children with chronic hepatitis B: durability of therapeutic responses and safety.
Jonas MM; Little NR; Gardner SD;
J Viral Hepat; 2008 Jan; 15(1):20-7. PubMed ID: 18088241
[TBL] [Abstract][Full Text] [Related]
5. Preliminary study on the efficacy and safety of lamivudine and interferon alpha therapy in decreasing serum HBV DNA level in HBV positive transgenic mice during pregnancy.
Li D; Xu DZ; Choi BC; Men K; Zhang JX; Lei XY; Yan YP
J Med Virol; 2005 Jun; 76(2):203-7. PubMed ID: 15834875
[TBL] [Abstract][Full Text] [Related]
6. [Lamivudine treatment consensus from relative experts].
Lamivudine Clinical Practice Group
Zhonghua Gan Zang Bing Za Zhi; 2002 Apr; 10(2):157-8. PubMed ID: 12108391
[No Abstract] [Full Text] [Related]
7. Efficacy of lamivudine on hepatitis B viral status and liver function in patients with hepatitis B virus-related hepatocellular carcinoma.
Kim JH; Park JW; Koh DW; Lee WJ; Kim CM
Liver Int; 2009 Feb; 29(2):203-7. PubMed ID: 18662281
[TBL] [Abstract][Full Text] [Related]
8. Successful treatment of hepatitis B virus infection with Lamivudine after heart transplantation.
Wang SS; Chou NK; Chi NH; Hsu RB; Huang SC; Chen YS; Yu HY; Tsao CI; Ko WJ; Lai MY; Chu SH
Transplant Proc; 2006 Sep; 38(7):2138-40. PubMed ID: 16980024
[TBL] [Abstract][Full Text] [Related]
9. Combination of baseline parameters and on-treatment hepatitis B virus DNA levels to start and continue patients with lamivudine therapy.
Yuen MF; Fung J; Seto WK; Wong DK; Yuen JC; Lai CL
Antivir Ther; 2009; 14(5):679-85. PubMed ID: 19704171
[TBL] [Abstract][Full Text] [Related]
10. [Comparison of lamivudine-induced HBsAg loss rate according to age in children with chronic hepatitis B].
Kim JM; Choe BH; Chu MA; Cho SM
Korean J Hepatol; 2009 Jun; 15(2):168-78. PubMed ID: 19581769
[TBL] [Abstract][Full Text] [Related]
11. [Application of serum hepatitis B virus large surface protein determination in lamivudine anti-viral therapy for patients with hepatitis B].
Li GY; Sheng JL; Huang HJ
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2008 Apr; 22(2):133-5. PubMed ID: 18574538
[TBL] [Abstract][Full Text] [Related]
12. Lamivudine treatment for reverse seroconversion of hepatitis B 4 years after allogeneic bone marrow transplantation.
Hashino S; Nozawa A; Izumiyama K; Yonezumi M; Chiba K; Kondo T; Suzuki S; Hige S; Asaka M
Bone Marrow Transplant; 2002 Feb; 29(4):361-3. PubMed ID: 11896435
[TBL] [Abstract][Full Text] [Related]
13. Withdrawal of lamivudine in HBeAg-positive chronic hepatitis B patients after achieving effective maintained virological suppression.
Yeh CT; Hsu CW; Chen YC; Liaw YF
J Clin Virol; 2009 Jun; 45(2):114-8. PubMed ID: 19451024
[TBL] [Abstract][Full Text] [Related]
14. [Treatment of hepatitis B].
Telegdy L
Orv Hetil; 2004 Nov; 145(45):2293-6. PubMed ID: 15573894
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a multicenter experience.
Tillmann HL; Hadem J; Leifeld L; Zachou K; Canbay A; Eisenbach C; Graziadei I; Encke J; Schmidt H; Vogel W; Schneider A; Spengler U; Gerken G; Dalekos GN; Wedemeyer H; Manns MP
J Viral Hepat; 2006 Apr; 13(4):256-63. PubMed ID: 16611192
[TBL] [Abstract][Full Text] [Related]
16. Hepatitis B core-related antigen assay is useful for monitoring the antiviral effects of nucleoside analogue therapy.
Tanaka E; Matsumoto A; Yoshizawa K; Maki N
Intervirology; 2008; 51 Suppl 1():3-6. PubMed ID: 18544941
[TBL] [Abstract][Full Text] [Related]
17. [Advance in clinical studies of the kinetics of hepatitis B virus].
Tang YT; Cao Q; Zhang DZ
Zhonghua Gan Zang Bing Za Zhi; 2010 Jan; 18(1):75-7. PubMed ID: 20128981
[No Abstract] [Full Text] [Related]
18. Severe reactivation of hepatitis B virus infection in a patient with hairy cell leukemia: Should lamivudine prophylaxis be recommended to HBsAg-negative, anti-HBc-positive patients?
Orlando R; Tosone G; Tiseo D; Piazza M; Portella G; Ciancia R; Martinelli V; Montante B; Rotoli B
Infection; 2006 Oct; 34(5):282-4. PubMed ID: 17033754
[TBL] [Abstract][Full Text] [Related]
19. Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: the case for continuous antiviral therapy.
Shouval D; Lai CL; Chang TT; Cheinquer H; Martin P; Carosi G; Han S; Kaymakoglu S; Tamez R; Yang J; Tenney D; Brett-Smith H
J Hepatol; 2009 Feb; 50(2):289-95. PubMed ID: 19070393
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of entecavir treatment for lamivudine-resistant hepatitis B over 3 years: histological improvement or entecavir resistance?
Suzuki Y; Suzuki F; Kawamura Y; Yatsuji H; Sezaki H; Hosaka T; Akuta N; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Miyakawa Y; Kumada H
J Gastroenterol Hepatol; 2009 Mar; 24(3):429-35. PubMed ID: 19226381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
